Update: Springworks Therapeutics announce the approval of FDA Gomekli ™ (Mirdametinib) for the treatment of adults and pediatric patients with NF1-PN

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.